IRCT20161212031362N4
Recruiting
Phase 3
Assessing the effect of Fampridine on cognitive outcome measures in multiple sclerosis patients: A double-blind, randomized, placebo-controlled study
Iranian Center of Neurological Research0 sites108 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Iranian Center of Neurological Research
- Enrollment
- 108
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Definite MS diagnosis according to McDonald 2017 criteria
- •Age between 18\-60 years
- •SDMT score below the 20th percentile of normative values
Exclusion Criteria
- •History of relapse within 2 months
- •History of seizure/epilepsy
- •History of major depression or psychosis
- •Reluctance to enroll in the study
- •Moderate or higher renal dysfunction (eGFR\=\< 50mL/min/1\.73m2\)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Famotidine for the improvement of cognitive impairments in COVID-19 patientsCOVID-19.COVID-19, virus identifiedU07.1IRCT20090117001556N138Tehran University of Medical Sciences50
Not yet recruiting
Phase 1
The effect of fampiridine on optic nerve imaging in patients with Anterior Ischemic Optic neuropathyIRCT20151123025202N35Shahid Beheshti University of Medical Sciences40
Recruiting
Phase 3
Fampridine effect on Parkinson disease symptomsParkinson disease.Parkinson's diseaseIRCT20230905059361N1Shahre-kord University of Medical Sciences62
Completed
Not Applicable
Effects of modafinil on cognitive functions in normal subjects using fMRIhealthy adultsJPRN-UMIN000007324ippon Medical School25
Recruiting
Phase 3
The effect of famotidine on reducing the side effects of prostate cancer radiotherapyIRCT20231121060132N1Kermanshah University of Medical Sciences50